Sampath Kumar Loganathan
In his lab, he utilizes the in vivo CRISPR methodology in mouse models of HNSCC and investigate oncological mechanisms that drive the HNSCC with the ultimate goal of developing novel drug targets to treat this deadly cancer. In collaboration with other faculty members in Head and Neck Surgery department, Cancer Research Program, RI-MUHC and Goodman Cancer Research Centre, he focuses on:
1) Establishing HNSCC mouse models of novel tumor suppressors
2) Investigating drug targets from GPCR superfamily using in vivo CRISPR screening in HNSCC mouse models and
3) Utilizing patient-derived xenograft models to study drug targets and oncological mechanisms in HNSCC
Dr. Sampath Loganathan received his Ph.D. from University of Alberta under the supervision of Dr. Joe Casey, Department of Biochemistry. In 2015, he joined the lab of Dr. Daniel Schramek as a Post-Doctoral Fellow at Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto. He studied Head and Neck Squamous Cell Carcinoma (HNSCC) using CRISPR based mouse models, ultra-sound guided lenti-viral injections, functional genomic tools and identified several novel tumor suppressors in HNSCC.